


## Methyl azetidine-3-carboxylate hydrochloride

<b>Cat. No.:</b>	HY-33615
<b>CAS No.:</b>	100202-39-9
<b>Molecular Formula:</b>	C <sub>5</sub> H <sub>10</sub> ClNO <sub>2</sub>
<b>Molecular Weight:</b>	151.59
<b>Target:</b>	ADC Linker; PROTAC Linkers
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### BIOLOGICAL ACTIVITY

<b>Description</b>	Methyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs<
<b>IC<sub>50</sub> &amp; Target</b>	Non-cleavable Linker
<b>In Vitro</b>	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov.* 2017;16(5):315-337.
- [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-985.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898      Fax: 609-228-5909      E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA